Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce A Chabner

Showing results (81-90 of 139) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Improving Prospects for Targeting RASHarshabad Singh, Dan L Longo, Bruce A Chabner
The New England Journal of Medicine|November 30, 2012
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
The Oncologist|June 18, 2002
Choosing chemotherapy for lung cancer based on cost: not yetThomas G Roberts, Thomas J Lynch, Bruce A Chabner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
The phase III trial in the era of targeted therapy: unraveling the "go or no go" decisionThomas G Roberts, Thomas J Lynch, Bruce A Chabner
The Oncologist|March 2, 2019
The Other Opioid Crisis: Just Another Drug Shortage?Tara E Soumerai, Mihir M Kamdar, Bruce A Chabner
The Oncologist|July 25, 2013
Clinical trial results: Sharing results, speeding discoveriesAntonio Tito Fojo, Susan E Bates, Bruce A Chabner
The Oncologist|July 2, 2013
Personalized medicine: hype or realityBruce A Chabner, Leif W Ellisen, A John Iafrate
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Pharmacodynamic biomarkers: falling short of the mark?Justin F Gainor, Dan L Longo, Bruce A Chabner
The Oncologist|December 1, 2010
New trends and novel treatment for hepatocellular carcinoma: a global perspectiveAndrew X Zhu, Bruce A Chabner, Kenneth K Tanabe
The New England Journal of Medicine|March 1, 2013
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
Pageof 14

Showing results (81-90 of 139) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2015
Improving Prospects for Targeting RASHarshabad Singh, Dan L Longo, Bruce A Chabner
The New England Journal of Medicine|November 30, 2012
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
The Oncologist|June 18, 2002
Choosing chemotherapy for lung cancer based on cost: not yetThomas G Roberts, Thomas J Lynch, Bruce A Chabner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
The phase III trial in the era of targeted therapy: unraveling the "go or no go" decisionThomas G Roberts, Thomas J Lynch, Bruce A Chabner
The Oncologist|March 2, 2019
The Other Opioid Crisis: Just Another Drug Shortage?Tara E Soumerai, Mihir M Kamdar, Bruce A Chabner
The Oncologist|July 25, 2013
Clinical trial results: Sharing results, speeding discoveriesAntonio Tito Fojo, Susan E Bates, Bruce A Chabner
The Oncologist|July 2, 2013
Personalized medicine: hype or realityBruce A Chabner, Leif W Ellisen, A John Iafrate
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2014
Pharmacodynamic biomarkers: falling short of the mark?Justin F Gainor, Dan L Longo, Bruce A Chabner
The Oncologist|December 1, 2010
New trends and novel treatment for hepatocellular carcinoma: a global perspectiveAndrew X Zhu, Bruce A Chabner, Kenneth K Tanabe
The New England Journal of Medicine|March 1, 2013
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
Pageof 14